Biotech Values

[rkrw]

Disagree with you on room for improvement...Who knows maybe a genr or someone else will blow the efficacy out rendering competition moot ala antegren....I'm sure that's what all the genr bulls are hoping for...here's some q&a comments from the alny conference call.

John Maraganore - Alnylam Pharmaceuticals - President, CEO,
Director
Yes. So, the name of here is to use intravitrial administration with this approach. We believe, although obviously this will have to be proven in clinical studies, that by blocking VEGF production, that we can achieve perhaps more durable effects, as compared to other therapies that are out there. Right now, Lucentis is going for every four-week dosing and Macugen is heading for every six-week dosing. Our goal is to achieve at least that, but with obviously improved efficacy.